PT-141

$366.00 USD

PT‑141 is a synthetic cyclic heptapeptide and melanocortin receptor agonist studied in preclinical and clinical research. Known for its selective activation of MC3R and MC4R, PT‑141 has been examined for its ability to modulate libido, arousal, and associated CNS signaling. Research models suggest potential effects in enhancing sexual motivation and neurologically mediated responses in experimental settings.

This peptide is used in laboratory research to explore neuroendocrine mechanisms tied to melanocortin signaling, central dopamine release, and behavioral modulation. It is frequently used in both animal and in vitro studies focused on receptor binding dynamics and signaling pathways.

PT‑141 (Bremelanotide) is a cyclic peptide analog of α‑MSH engineered to selectively activate melanocortin receptors—MC3R and MC4R—primarily within the central nervous system. Early preclinical research demonstrated that PT‑141 induces sexual arousal mechanisms in animal models, including penile erections in rats via central receptor activation and increased c‑Fos expression in hypothalamic neurons (Molinoff et al., 2003) ResearchGate+6PubMed+6Oxford Academic+6.

In rodent behavioral assays, PT‑141 triggered elevated proceptive sexual behaviors and restored mating performance in pain-modulated models, suggesting central modulation of sexual motivation pathways ResearchGate. Unlike traditional vasodilatory-based peptides, PT‑141 operates through central neurotransmitter modulation.

Human clinical trials further examined PT‑141's efficacy. In the RECONNECT phase III trials, subcutaneous administration significantly increased sexual desire and decreased associated distress in premenopausal women with hypoactive sexual desire disorder, demonstrating statistical significance and favorable tolerability profiles Wikipedia+15PMC+15PMC+15. These findings support PT‑141 as a functional melanocortinergic agent influencing CNS-mediated sexual response.

Mechanistically, PT‑141 is proposed to elevate dopamine levels in the medial preoptic area of the hypothalamus, a key center for sexual arousal. By activating MC4R pathways, it may enhance libido and central motivational states in both male and female contexts (Clin Res & reviews) Men's Reproductive Health+1DrugBank+1.

Pharmacokinetic evaluations in healthy subjects and individuals with mild-to-moderate erectile dysfunction have demonstrated dose-dependent effects on erection duration, showing increased rigidity and onset latency without significant systemic blood pressure or hormonal side effects (Molinoff PB et al., 2004) WJMH+2PubMed+2northamptonintegrativemedicine.com+2.

Together, this body of work models PT‑141 as a centrally acting melanocortin receptor agonist with effects on sexual motivation and neuroendocrine signaling. Studies emphasize its ability to induce central arousal responses through peptide-based receptor modulation, distinguishing it from peripherally acting agents. Continued research explores its impact across CNS-driven behaviors and neuropeptide pathways.

Research & References:

Molinoff PB et al., “PT‑141: a melanocortin agonist for the treatment of sexual dysfunction,” Ann N Y Acad Sci., 2003. ResearchGate+7PubMed+7northamptonintegrativemedicine.com+7
Farmer MA et al., “Preclinical CNS effects of bremelanotide on female sexual behavior,” J Sex Med., 2006. PMC+14ResearchGate+14Oxford Academic+14
Kingsberg SA et al., “RECONNECT studies: Bremelanotide improves sexual desire in premenopausal women,” Womens Health (Lond)., 2019. DrugBank+3PMC+3PMC+3